Clinical Trial Update: SRT for Residual Oligometastases of NSCLC After 3rd Generation EGFR-TKIs [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating stereotactic radiotherapy (SRT) for residual oligometastases in non-small cell lung cancer after third-generation EGFR-TKI the…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Snippet

Sponsor: Fudan University | Conditions: NSCLC Stage IV, EGFR Activating Mutation | Phase 2 | Status: COMPLETED